In June 2020, the FDA approved Keytruda (pembrolizumab) as an initial therapy for advanced colorectal cancer. This approval was based on the results from the KEYNOTE-177 study. In this study, Keytruda was more successful than chemotherapy in delaying progression of certain types of colorectal cancers. (11/25/20)
The following are studies enrolling people with advanced colorectal cancer.
NCT04895722: Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer. The purpose of this study is to look at the safety of a combination drug pembrolizumab/quavonlimab compared with four other treatments in patients with Microsatellite Instability-High (MSI-H) advanced colorectal cancer.
A number of other clinical trials for patients with colorectal cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.